Who are Low-Dose Lidocaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Remifentanil+Lidocaine, Suzetrigine (SUZ), intraarticular injection with ropivacaine, Exparel/bupivacaine mixture, Propofol/Lidocaine, Dexamethasone+ Bupivacaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-lidocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Low-Dose Lidocaine — Competitive Intelligence Brief

Low-Dose Lidocaine (Low-Dose Lidocaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic / sodium channel blocker. Area: Pain Management / Neurology.

marketed Local anesthetic / sodium channel blocker Voltage-gated sodium channels Pain Management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Low-Dose Lidocaine (Low-Dose Lidocaine) — The Methodist Hospital Research Institute. Low-dose lidocaine blocks sodium channels and modulates inflammatory and neuropathic pain pathways at sub-anesthetic concentrations.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low-Dose Lidocaine TARGET	Low-Dose Lidocaine	The Methodist Hospital Research Institute	marketed	Local anesthetic / sodium channel blocker	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)
intraarticular injection with ropivacaine	intraarticular injection with ropivacaine	Hvidovre University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Propofol/Lidocaine	Propofol/Lidocaine	NYU Langone Health	marketed	Intravenous anesthetic combination	GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
Dexamethasone+ Bupivacaine	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic / sodium channel blocker class)

The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-Dose Lidocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-lidocaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab